Clinical niche sought for platelet-boosting drugs.
Jenks
S
S
D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D009363:Neoplasm Proteins; D010976:Platelet Count / Q000187:drug effects; D011518:Proto-Oncogene Proteins / Q000187:drug effects; D018121:Receptors, Cytokine / Q000187:drug effects; D011971:Receptors, Immunologic / Q000187:drug effects; D053628:Receptors, Thrombopoietin; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D013926:Thrombopoietin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D011971:Receptors, Immunologic; D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; D013926:Thrombopoietin